Overview of the postulated mechanisms linking cancer and thrombosis.

ten Cate H, Falanga A.

Pathophysiol Haemost Thromb. 2008;36(3-4):122-30.

Hemostatic complications of angiogenesis inhibitors in cancer patients.

Elice F, Jacoub J, Rickles FR, Falanga A, Rodeghiero F.

Am J Hematol. 2008;83(11):862-70.

Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation.

Landolfi R, Di Gennaro L, Falanga A.

Leukemia. 2008;22(11):2020-8.

Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera.

Marchetti M, Castoldi E, Spronk HM, van Oerle R, Balducci D, Barbui T, Rosing J, Ten Cate H, Falanga A.

Blood. 2008;112(10):4061-8.

Hypercoagulability and tissue factor gene upregulation in hematologic malignancies.

Falanga A, Barbui T, Rickles FR. Semin Thromb Hemost. 2008;34(2):204-10.

Management of venous thromboembolism in cancer patients: ESMO clinical recommendations.

Mandalà M, Falanga A, Roila F; ESMO Guidelines Working Group.

Ann Oncol. 2008;19 Suppl 2:ii126-7.

Endothelial capillary tube formation and cell proliferation induced by tumor cells are affected by low molecular weight heparins and unfractionated heparin.

Marchetti M, Vignoli A, Russo L, Balducci D, Pagnoncelli M, Barbui T, Falanga A.

Thromb Res. 2008;121(5):637-45.